Photo: Nanfang Plus

The National Health Commission of China has signaled strong support for the Guangdong-Macao In-Depth Cooperation Zone in Hengqin to pioneer innovative medical policies, particularly in stem cell research and clinical applications.

The move aims to leverage the Guangdong-Hong Kong-Macao Greater Bay Area as a testing ground for healthcare reforms and to refine the evaluation framework for cell therapy products.

Stem cell research has become a focal point in global biomedical innovation. In 2025, China approved its first stem cell therapy drug, marking a significant milestone in the sector. The National Medical Products Administration has pledged expedited reviews for eligible stem cell products, accelerating their path to market.

Hengqin is encouraged to define strategic priorities and research task lists in the stem cell field, while leading enterprises undertake critical scientific projects. Pilot projects for medical insurance coverage of stem cell therapies have also begun, paving the way for broader clinical adoption.

As part of its “Four New” industries, the healthcare sector is a key driver for Hengqin’s efforts to diversify Macao’s economy. The island is focusing on stem cell therapies, medical aesthetics, and other specialized projects, aiming to establish a high-standard biomedical and wellness hub.